Welcome to PsorVal.net | DermaSolve.net !

 

Your Source for Psor-Val | DermaSolve | Absorbase

 

 Serving Treatment Solutions for Psoriasis, Eczema, Dry Skin 

 

Providing News, Views, Tips and Tricks

along with great products for that   "Healthy You" 


MedWorm: Psoriasis

Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients (Thu, 30 Oct 2014)
In conclusion, MTX induce apoptosis through oxidative stress by reducing NO and increasing caspase-3 levels. MTX-induced apoptosis may account for the beneficial effect of MTX treatment in psoriasis patients, which is characterized by acanthosis. (Source: Clinical and Experimental Medicine) MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space...
>> read more

Scalp psoriasis vs. seborrheic dermatitis: What's the difference? (Thu, 30 Oct 2014)
(Source: MayoClinic.com - Ask a Specialist)
>> read more

Secukinumab efficacy and safety in Japanese patients with moderate‐to‐severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo‐controlled, phase 3 study (Thu, 30 Oct 2014)
Abstract Secukinumab, a fully human anti‐IL‐17A monoclonal antibody, neutralizes IL‐17A, a key cytokine in the pathogenesis of psoriasis. Efficacy and safety of secukinumab was evaluated in Japanese patients with moderate‐to‐severe plaque psoriasis as part of a large Phase 3 global study (ERASURE). In this 52‐week, double‐blind study (ClinicalTrials.gov Identifier: NCT01365455, JapicCTI‐111529), 87 patients from Japan (11.8% of 738 patients randomized in the overall study population) were equally randomized to receive secukinumab 300 mg or 150 mg, or placebo once weekly at baseline and at Weeks 1, 2, 3 and 4, then every 4 weeks. Co‐primary endpoints (Week 12) were ≥75% improvement in psoriasis area‐and‐severity index (PASI 75) from baseline and a score of 0 (clea...
>> read more

IL6 −174G>C polymorphism is associated with an increased risk of psoriasis but not response to treatment (Thu, 30 Oct 2014)
This article is protected by copyright. All rights reserved. (Source: Experimental Dermatology)
>> read more

Balance of Treg versus T‐effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol‐betamethasone dipropionate (CBD) ointment (Thu, 30 Oct 2014)
This article is protected by copyright. All rights reserved. (Source: Experimental Dermatology)
>> read more

Serum prolactin levels in psoriasis and its association with disease activity: A case-control study (Thu, 30 Oct 2014)
Conclusion: PRL may have a role to play in the etiopathogenesis of psoriasis. However, further studies with large sample size should be carried out so as to validate this hypothesis. (Source: Indian Journal of Dermatology) MedWorm Sponsor Message: MedWorm Search is coming back soon. Watch this space...
>> read more

An open label prospective randomized trial to compare the efficacy of coal tar-salicylic acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis (Thu, 30 Oct 2014)
Conclusion: Topical nightly application of calcipotriol/betamethasone dipropionate ointment leads to an initial, more rapid reduction in disease severity, but the overall outcome parameters are comparable in the two treatment groups. (Source: Indian Journal of Dermatology)
>> read more

Hepcidin expression in psoriasis patients (Thu, 30 Oct 2014)
Conclusions: We think that studies on hepcidin expression in psoriatic plaques will contribute to our understanding the role of iron and hepcidin in the pathogenesis of psoriasis. (Source: Indian Journal of Dermatology)
>> read more

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer (Thu, 30 Oct 2014)
In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA. (Source: Indian Journal of Dermatology)
>> read more

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis (Thu, 30 Oct 2014)
ConclusionBy Week 12, nearly all patients with PP, EP and GPP achieved PASI75. The safety profile was consistent with reported results and no unexpected safety signals were observed. (Source: Journal of the European Academy of Dermatology and Venereology)
>> read more

 

Scan our QR Code to your Smart Phone / iPhone Users download QR Reader from Tap Media http://www.TapMedia.co.uk 

Real Time Web Analytics


International Clients, After adding products to Cart - Refresh your browser if you do not see the "International Checkout" Button

Psor-Val Zinc Spray, DermaSolve Psoriasis Care Products and

Absorbase Cream for Moisturizing Skin Care.

 

Treatment Solutions and Products for Psoriasis, Eczema, Dry Skin. Natural Care for that Healthy You!